hemophilia A

Pfizer, Sangamo flesh out hemophilia gene therapy data ahead of phase 3
Pfizer, Sangamo flesh out hemophilia gene therapy data ahead of phase 3
Fierce Biotech
Pfizer
Sangamo BioSciences
hemophilia A
clinical trials
gene therapy
giroctocogene fitelparvovec
Flag link:
BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment
BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment
BioSpace
Biomarin
clinical trials
hemophilia A
valoctocogene roxaparvovec
Flag link:
BioMarin gene therapy shows sustained benefit in hemophilia A study
BioMarin gene therapy shows sustained benefit in hemophilia A study
Seeking Alpha
Biomarin
hemophilia A
clinical trials
gene therapy
valoctocogene roxaparvovec
Flag link:
Regeneron to expand development deal with Intellia Therapeutics
Regeneron to expand development deal with Intellia Therapeutics
Marketwatch
Regeneron
Intellia Therapeutics
hemophilia A
hemophilia B
CRISPR
drug development
Flag link:
BioMarin's Novel Treatment Promises to Disrupt Competitors
BioMarin's Novel Treatment Promises to Disrupt Competitors
Motley Fool
Biomarin
gene therapy
valrox
hemophilia A
Flag link:
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review
Motley Fool
FDA
Biomarin
priority review
valrox
gene therapy
hemophilia A
Flag link:
Novimmune unit nabs Takeda milestone payment for hemophilia work
Novimmune unit nabs Takeda milestone payment for hemophilia work
Fierce Biotech
Takeda
Light Chain Bioscience
Novimmune
R&D
Hemlibra
hemophilia A
Flag link:
Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World
Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World
Forbes
Biomarin
valrox
gene therapy
hemophilia A
Flag link:
Takeda Eyes 12 New Drug Approvals by 2024, Hemophilia Gene Therapy May Not be a Competitor
Takeda Eyes 12 New Drug Approvals by 2024, Hemophilia Gene Therapy May Not be a Competitor
BioSpace
Takeda
drug approvals
hemophilia A
TAK-754
TAK-748
Flag link:
Generation Bio grabs a $110M round to ramp up work on next-gen gene therapies
Generation Bio grabs a $110M round to ramp up work on next-gen gene therapies
Fierce Biotech
Generation Bio
hemophilia A
phenylketonuria
gene therapies
Flag link:
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Value-based pricing for gene therapy? Maybe not ready for hemophilia
Biopharma Dive
Biomarin
hemophilia
hemophilia A
gene therapy
valoctocogene roxaparvovec
uniQure
hemophilia B
etranadez
Flag link:
Sigilon Therapeutics approaches the clinic
Sigilon Therapeutics approaches the clinic
EP Vantage
Sigilon
orphan drug
hemophilia A
Eli Lilly
diabetes
Flag link:
BioMarin talks down worries on gene therapy data differences
BioMarin talks down worries on gene therapy data differences
Biopharma Dive
Biomarin
gene therapy
hemophilia A
valrox
Flag link:
BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end
BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end
Fierce Biotech
Biomarin
hemophilia
gene therapy
valoctocogene roxaparvovec
valrox
hemophilia A
Flag link:
Bayer recalls mislabeled vials of hemophilia A treatment
Bayer recalls mislabeled vials of hemophilia A treatment
Fierce Pharma
Bayer
product recalls
hemophilia A
Kogenate FS
Jivi
Flag link:
Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy
Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy
Endpoints
Biomarin
hemophilia A
gene therapy
FDA
Sangamo
Pfizer
Flag link:
Sangamo backs up early success for hemophilia gene therapy
Sangamo backs up early success for hemophilia gene therapy
Biopharma Dive
Sangamo
gene therapy
hemophilia A
SB-525
Pfizer
Spark Therapeutics
Biomarin
Flag link:
How BioMarin May Revolutionize the Hemophilia Treatment Market
How BioMarin May Revolutionize the Hemophilia Treatment Market
Motley Fool
Biomarin
gene therapy
hemophilia A
valrox
Flag link:
Does Sangamo Have the Best Gene Therapy Program Now?
Does Sangamo Have the Best Gene Therapy Program Now?
Motley Fool
Sangamo Therapeutics
gene therapy
SB-525
hemophilia A
Flag link:
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:

Pages